New Two-Pronged drug joins fight against advanced lung cancer
NCT ID NCT04736823
Summary
This study is testing whether a new drug called AK112, which targets two cancer pathways at once, works better when combined with standard chemotherapy for advanced non-small cell lung cancer (NSCLC). It involved 265 adults with stage IIIB/C or IV NSCLC to see if the combination can shrink tumors and help patients live longer. The main goal is to measure how well and how safely the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guanzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.